Skip to content

STARBRITE: A Randomized Pilot Trial of BNP-Guided Therapy in Patients With Advanced Heart Failure

Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natriuretic Peptide Levels Versus the Clinical Congestion Score

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00484770
Acronym
STARBRITE
Enrollment
135
Registered
2007-06-11
Start date
2003-02-28
Completion date
2005-08-31
Last updated
2023-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure

Keywords

heart failure, brain natriuretic peptide

Brief summary

The primary hypothesis is that, in patients with advanced heart failure, an outpatient fluid management strategy guided by BNP levels and clinical targets will lead to fewer days hospitalized or dead over a 3-month period compared to an outpatient fluid management strategy using clinical targets alone.

Detailed description

STARBRITE will test the hypothesis that a defined fluid management strategy, tailored to specific symptoms and physiological targets, will improve morbidity and mortality in the advanced heart failure population. Individual targets for each patient will be based on the outcome of the index hospitalization, during which therapy is adjusted to optimize clinical status, blood pressure, and renal function. Identifying a standard fluid management strategy may be an important way to limit the complications of diuretic therapy and the duration of hospitalization for these patients. In addition, a standard approach may provide objective criteria that can be used to systematically deliver care in many types of clinical settings. In this study, patients will be randomized to two strategies of outpatient fluid management: 1) the Congestion Score Strategy and, 2) the BNP Strategy.

Interventions

DEVICEBrain Natriuretic Peptide Levels -- Diagnostic testing
OTHERclinical assessment

Sponsors

American Heart Association
CollaboratorOTHER
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients admitted with NYHA class III/IV symptoms of heart failure 2. Left ventricular ejection fraction ≤35% 3. Will have received at least one dose of intravenous diuretics during the current hospitalization 4. Prior to discharge, has received heart failure education and has learned about daily weights, and fluid, sodium, and dietary restrictions 5. Able to return for follow-up care at the Brigham and Women's Hospital Cardiomyopathy Clinic or the Duke Heart Failure Management Program 6. Has regular access to a telephone 7. ≥18 years of age

Exclusion criteria

1. Moderate to severe valvular stenosis 2. Admitted with acute coronary syndrome 3. Creatinine \>3.5 4. Renal failure on hemodialysis 5. Pregnant or lactating

Design outcomes

Primary

MeasureTime frame
Number of days neither hospitalized nor dead from the date of the first clinic visit to 90 days thereafter90 day follow up

Secondary

MeasureTime frame
1. Number of days not dead from the date of the first clinic visit to 90 days thereafter 2.Number of days not hospitalized from the date of the first clinic visit to 90 days thereafter90 day follow up

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026